Dr. Pham Hung Van
Hochiminh City Society of Clinical Microbiology; Phan Chau Trinh University
Title of the talk: Antibiotic Resistance Challenge in Vietnam – Situation and Solutions vectors
Abstract
Doctors today are hard to select the effective antibiotic regimen for treatment of bacterial infections caused by hospital-acquired bacteria because these agents are among the ESKAPE pathogens: E. faecium resistant to vancomycin has been increasingly recognized from clinical isolates, methicillin-resistant S. aureus (MRSA) in most of the hospitals is usually more than 70%, K. pneumoniae and other Enterobacteriaceae producing ESBL have been reported no less than 50% in large hospitals, more than 80% of A. baumannii are extremely drug resistance (XDR), more than 30% of P. aeruginosa are multi-drug resistance (MDR), and more and more carbapenem-resistant Enterobacteriaceae have been recognized in the clinical isolates. It is not easy dealing with these pathogens because E. faecium resistant to vancomycin are virtually untreatable by other antibiotics, MRSA are resistant to all beta-lactam and vancomycin failure rate is over 80% if the MIC over 1.5mcg/ml, K. pneumoniae and E. coli producing ESBL are resistant to all cephalosporins, A. baumannii XDR are only sensitive to colistin and tigecycline, but both antibiotics are not effective with monotherapy, P. aeruginosa MDR are the challenge in selecting antibiotics treatment because the quick development of carbapenem group 2 resistance, and finally it is almost the end of choice of antibiotic treatment for carbapenem-resistant Enterobacteriaceae. Solutions for this situation should include: (1) The competent authorities of the state must strictly and seriously control the quality of antibiotics and strictly control the use of antibiotics in humans and in livestock; (2) The hospital must effectively monitor the use of antibiotics in the hospital; (3) Clinical microbiology lab must be able to detect the above-mentioned resistance to help physicians to adjust the antibiotic treatment in a reasonable way; (4) Clinicians must be able to identify emerging resistance when reading antibiotic susceptibility results to avoid the use of resistant antibiotics as well as to adjust the antibiotics treatment to achieve pKpD effects.
Biography
Dr. Pham Hung Van has completed his Medical Doctor in 1978 and his Philosophy Doctor of Epidemiology and Microbiology in 1995 from the University of Medicine and Pharmacy in Ho Chi Minh City. He was the Lecturer of this university from 1978 to 2013. He is the Principal Investigator of ANSORP from 1998, President of the Vietnam Association of Medical Molecular Biology from 2007, President of HCMC Society of Clinical Microbiology from 2013, and Prevost of Phan Chau Trinh University from 2017. His studies have focused on the surveillance of the major bacterial pathogens and the methods to detect the micro-organism pathogens from clinical samples. He has written 3 books published by the Medical Publisher (Nha Xuat Ban Y Hoc) 31 international papers (15 first author, 15 co-authors), 52 national papers (23 first author, 27 co-authors).
Publications: ResearchGate.